UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

Schedule 14A Information

 

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

 

Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

 

Check the appropriate box:

 

Preliminary Proxy Statement
   
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
   
Definitive Proxy Statement
   
Definitive Additional Materials
   
Soliciting Material Pursuant to §240.14a-12

 

Lineage Cell Therapeutics, Inc.

(Name of Registrant as Specified in Its Charter)

 

 

(Name of Person(s) Filing Proxy Statement if other than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

 

No fee required.
   
Fee paid previously with preliminary materials.
   
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

 

 

 

 

 

 

 

 

 

 


Lineage Cell Therapeutics (AMEX:LCTX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 Lineage Cell Therapeutics 차트를 더 보려면 여기를 클릭.
Lineage Cell Therapeutics (AMEX:LCTX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 Lineage Cell Therapeutics 차트를 더 보려면 여기를 클릭.